

Next steps in ATMPs and beyond 24-25 June 2024 Agenda Preview

Monday	, 24 June 2024				
9:00	Welcome and Introduction	Falk Klar, PDA Europe			
	Welcome from the Co-Chairs	Renske ten Ham, University Medical Center Utrecht Richard Denk, SKAN			
Opening Plenary					
	Keynote: 7 Things I Wish I Knew Before Undergoing Gene Therapy	Patient Advocate			
	EMA's Experience in the Development Support and Approval of Gene Therapy Medicinal Products	EMA			
	Enhancing Strategic Decision-Making for ATMP Development & Commercialization: The Role of Supply Chain Business Intelligence	F. Hoffmann-La Roche			
	Q&A, Discussion				
11:00	Networking Coffee Break, Poster Session & Exhibition				
Session 1: Cha	Session 1: Challenges in Manufacturing				
	The Challenges of the Innovative Exosomes-based Therapies – Case Study	EXO Biologics			
	'Spilling the Tea' on Leaks in Autologous CAR T Manufacturing	Bristol Myers Squibb			
	Visual Inspection & Particle Life Cycle Management in CGT Products - Same, Same but Different?	Clear Solutions Laboratories & Takeda			



Next steps in ATMPs and beyond 24-25 June 2024 Agenda Preview

	Q&A, Discussion				
13:00	Networking Lunch Break, Poster Session & Exhibition				
13:40	LIVE Guided Poster Walk Engage with our Poster Presenters in our Exhibition Hall				
Session 2: From	Session 2: From Development to Commercialization				
	Interactive Questionnaire Session	Via Mentimeter			
	Treatment with Tumor-Infiltrating Lymphocytes (TILs) for Patients with Advanced Melanoma: From a Randomized Phase 3 Trial in Academia towards Marketing Authorization	Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital			
	Decentralizing CAR-T Production: Proof of Concept Network Experience with an Academic CAR-T	IDIBAPS hospital clinic Barcelona			
	Decentralized Manufacturing of Autologous ATMPs: How Technology Innovation Fosters Regulatory Compliance	Tigen Pharma			
	Q&A, Discussion				
15:50	Networking Coffee Break, Poster Session & Exhibition				
Session 3: Quality Control					
	Addressing the Challenges: Alternative Methods for ATMP Analytics Testing	Merck			
	Viral Control Strategy for Allogeneic Cell Therapy	Sanofi			
	Challenges in Developing a Change Control System for an ATMP Manufacturing Site	Kite Pharma			
	Q&A, Discussion				



Next steps in ATMPs and beyond 24-25 June 2024 Agenda Preview

17:50	End of Conference Day 1 & Networking Event				
Tuesday	Tuesday, 25 June 2024				
9:00	Welcome to Day 2	Renske ten Ham, University Medical Center Utrecht Richard Denk, SKAN			
		Thomas de ling ord in			
Session 5: Reg	gulatory Session				
	Navigating Regulatory Challenges: Insights from Developing ATMPs through GMP/GDP/GCP	PMS Process Management System			
	USP Microbiology Updates on RMM for Short Life Products	Steed MircroBio LLC			
	Title to be announced	Paul-Ehrlich Institut			
	Q&A, Discussion				
10:35	Networking Coffee Break, Poster Session & Exhibition				
Session 6: New Technologies					
	One-Step Instant MSC Product Accompanying Autologous Chondron Transplantation for Focal Articular Cartilage Lesions of the Knee: Preliminary Results of a Cross-Over Randomized Controlled Trial	UMC Utrecht			
	How AI Can Transform ATMP Development	Blackfin BioPharma Advisors			
	Q&A, Discussion				



Next steps in ATMPs and beyond 24-25 June 2024 Agenda Preview

12:15	Networking Lunch Break, Poster Session & Exhibition			
Closing Plenary				
	Interactive Questionnaire Session	Via Mentimeter		
	Points to Consider for Classification, Manufacture, and Control of Plasmids and Vectors Used in ATMP Production	Valsource		
	Inspections of ATMP Production Sites and Hospital Exemption Applications	Health and Youth Care Inspectorate		
14:10	Networking Coffee Break, Poster Session & Exhibition			
	Passport Raffle via PDA Europe			
	Fireside Chat: Swissmedic Q&A Document on EU GMP Annex 1 and Requirements for ATMPs	Swissmedic & SKAN		
	Closing Panel Discussion			
	Join our Discussion with Experts from the Industry and Regulatory			
	Co-Chairs Conference Summary	Renske ten Ham, University Medical Center Utrecht Richard Denk, SKAN		
	Closing Remarks & Farewell	Falk Klar, PDA Europe		
16:10	End of Conference			

The agenda is subject to change without notice, Speakers are invited pending confirmation.